← Eichor
Condition: Kras Mutant Non Small Cell Lung Cancer Nsclc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Kras Mutant Non Small Cell Lung Cancer Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT
Phase 3 · 50 location(s) · Merck Sharp & Dohme LLC · NCT07554339A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · 419 location(s) · Eli Lilly and Company · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 · 35 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06343402A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung C
Phase 3 · 225 location(s) · Merck Sharp & Dohme LLC · NCT06345729KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT05254184TCR1188-ABC Cells in KRAS-mutated Cancers
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07594067Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · 366 location(s) · Eli Lilly and Company · NCT06890598Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Phase 2 · 3 location(s) · Jianxing He · NCT07492342MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 52 location(s) · Eli Lilly and Company · NCT06586515A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-
Phase 3 · 195 location(s) · Merck Sharp & Dohme LLC · NCT07190248MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Phase 3 · 72 location(s) · Merck Sharp & Dohme LLC · NCT07431827A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06582771BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 · 17 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06917079Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1 · 9 location(s) · Revolution Medicines, Inc. · NCT07349537Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherap
Phase 1/Phase 2 · 4 location(s) · Auricula Biosciences Inc. · NCT07148128Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 17 location(s) · Revolution Medicines, Inc. · NCT06040541Ladarixin With Sotorasib in Advanced NSCLC
Phase 1 · 6 location(s) · NYU Langone Health · NCT05815173A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral On
Phase 1 · 9 location(s) · Kestrel Therapeutics, Inc. · NCT07458347
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.